Stay updated with breaking news from Tris Prevailed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Case Name: Tris Pharma, Inc. v. Teva Pharms. USA, Inc., Civ. No. 20-5212 (KM)(ESK) (D.N.J. Aug. 16, 2022) (McNulty, J.) Drug Product and Patent(s)-in-Suit: QuilliChew ER®...
Quillivant XR® (methylphenidate (“MPH”)) Case Name: Tris Pharma, Inc. v. Actavis Labs. FL, Inc., No. 14-1309-CFC, 2020 WL 7028456 (D. Del. Nov. 30, 2020) (Connolly, J.) Drug Product and Patent(s)-in-Suit: Quillivant XR® (methylphenidate (“MPH”)); U.S. Patents Nos. 8,465,765 (“the ’765 patent”), 8,563,033 (“the ’033 patent”), 8,778,390 (“the ’390 patent”), 8,956,649 (“the ’649 patent”), and 9,040,083 (“the ’083 patent”) Nature of the Case and Issue(s) Presented: Tris sued Actavis alleging infringement of 21 claims from the five patents-in-suit. In respo...